{"filings":[{"id":2060804,"accession_number":"0001193125-26-333813","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-08-05T11:02:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.","Cash $106.3M at June 30, 2026; combined with $200M July offering funds through Phase 3 topline.","Bempikibart showed 35.3% mean SALT reduction at Week 36; 40% SALT-20 response (mITT) in SIGNAL-AA Part B.","Registration-directed program for severe/very severe AA expected to start 1H2027, pending regulatory discussions.","ADX-914-XL (half-life extended anti-IL-7Rα) advancing in preclinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1666836,"accession_number":"0001193125-26-304964","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-07-15T21:18:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Q32 Bio prices $18.25/share offering of 6M shares and pre-funded warrants; net proceeds ~$187.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,027,399 shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499.","Net proceeds estimated at $187.6M (or $215.8M if underwriters' option exercised in full).","Proceeds for working capital, research, clinical development, and commercialization of bempikibart.","Underwriters: Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer; close expected July 16, 2026.","Pre-funded warrants exercisable at $0.0001/share, subject to ownership limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1592598,"accession_number":"0001193125-26-301520","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-07-13T12:39:54+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio announces topline results from SIGNAL-AA Phase 2a Part B trial of bempikibart in alopecia areata","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Topline results from 36-week Part B of SIGNAL-AA Phase 2a trial for bempikibart (ADX-914) in alopecia areata announced on July 13, 2026.","Presentation filed as Exhibit 99.1 contains detailed efficacy, safety, and biomarker data; no numerical results provided in the 8-K body.","Company cautions that additional data analyses may not support current beliefs; risks include trial costs, funding needs, and regulatory uncertainties.","Forward-looking statements highlight potential differences between topline and final results; stock may react to data in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1591878,"accession_number":"0001193125-26-301464","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-07-13T11:09:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio: positive 36-week Phase 2a data for bempikibart in alopecia areata; registration trial planned H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis at Week 36.","40% (10/25) mITT and 30.3% (10/33) ITT achieved SALT-20; 44% achieved SALT-30 and SALT-50.","No serious adverse events or Grade 3+ treatment-related AEs; mild injection site reaction in 36.3% of patients (4% of doses).","Company paid off remaining $6.8M loan to Silicon Valley Bank on June 24, 2026; loan agreement terminated.","Plans to advance bempikibart into registration-directed program in first half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083597,"accession_number":"0001193125-26-272562","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-06-16T20:01:35+00:00","items":["5.07"],"status":"ready","headline":"Q32 Bio stockholders elect Class II directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos as Class II directors for three-year terms ending 2029.","Ratification of Ernst & Young as independent auditor for FY 2026 passed with 11,821,046 votes for, 7,909 against.","Non-binding advisory vote on named executive officer compensation approved with 8,072,067 for, 400,598 against.","Turnout was 75.71% (11,833,800 of 15,629,463 outstanding shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":695358,"accession_number":"0001193125-26-241846","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-05-27T20:01:51+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.","Investors include BVF Partners, RA Capital, OrbiMed, Atlas Venture; led by BVF.","Closing expected May 28, 2026; net proceeds to advance bempikibart clinical trials and for working capital.","Registration rights agreement filed to register resale of shares and warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94504,"accession_number":"0001193125-26-205006","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q1 2026 net loss of $7.6M; bempikibart trial on track for mid-2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $50.8M at Mar 31; plus $14.2M ATM proceeds post-Q and milestone payments fund into 1H 2028.","Net loss $7.6M ($0.54 EPS) vs $11.0M ($0.90) in Q1 2025.","Bempikibart Part B SIGNAL-AA 36-wk topline data readout on track for mid-2026; first OLE patient dosed.","Completed $10.5M registered direct offering in Feb 2026 (1.7M shares/pre-funded warrants at $3.90).","R&D expenses fell to $3.2M from $7.1M due to headcount reduction and ADX-097 sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94503,"accession_number":"0001193125-26-177178","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio launches $75M ATM equity offering after exhausting prior $14.2M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold all $14.2M from prior ATM program; offering terminated as of April 24, 2026.","New prospectus supplement filed for up to $75M in common stock via Cantor Fitzgerald.","Shares offered under effective shelf registration statement (Form S-3, filed April 2025).","Goodwin Procter LLP issued legal opinion on the additional shares (Exhibit 5.1).","No offer or sale in jurisdictions where unregistered or unlawful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106939,"accession_number":"0001193125-26-129431","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Q32 Bio enters ATM sales agreement for up to $14.2M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. for at-the-market sales.","May sell shares with aggregate offering price up to $14.2 million via prospectus supplement filed March 27, 2026.","Sales made on Nasdaq or other trading markets; Agent receives 3.0% cash commission on gross proceeds.","Company not obligated to sell any shares; can suspend or terminate offering on notice to Agent.","Uses existing shelf registration statement Form S-3 (File No. 333-286491) effective April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106938,"accession_number":"0001193125-26-099328","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.","Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.","Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.","Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.","Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106937,"accession_number":"0001193125-26-054711","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.","Offering price equals Feb 13 closing price; pre-funded warrants exercisable at $0.0001/share.","Net proceeds for working capital, including advancing bempikibart for alopecia areata into future trials.","Closing expected Feb 18, 2026; led by new institutional investor with participation from existing investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123267,"accession_number":"0001193125-25-326821","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Q32 Bio director Mark Iwicki withdraws resignation, remains Board Chair and committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Iwicki had previously notified intention to resign from Board effective Dec 31, 2025 to focus on CEO role at Inhibikase Therapeutics.","On Dec 17, 2025, Iwicki withdrew resignation with full Board support, effective immediately, citing reduced board commitments.","He will continue as Chair of the Board and Compensation Committee, and as a member of the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123266,"accession_number":"0001193125-25-303115","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).","Eligible for up to $92.5M in development/regulatory milestones and $487.5M commercial milestones.","Tiered royalties on future sales of ADX-097 from low single-digit to mid-teen percent.","Cash runway extended into H2 2027; topline SIGNAL-AA Part B data expected mid-2026.","Q32 retains tissue-targeted complement platform including ADX-096; evaluating strategic options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123265,"accession_number":"0001193125-25-278805","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.","Cash and equivalents $49.0M as of Sep 30, 2025, expected to fund operations into 2027.","Net loss $7.4M ($0.60 per share) vs $17.6M ($1.46 per share) in Q3 2024, driven by lower R&D spend.","R&D expenses decreased to $3.6M from $14.3M; G&A to $4.0M from $4.5M year-over-year.","Emerging signs of clinical activity observed; preliminary PK shows steady-state drug concentration achieved 9 weeks earlier with loading regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123264,"accession_number":"0001193125-25-244262","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.","Enrollment exceeded initial target of ~20 patients, total 33 patients enrolled due to patient demand.","Part B includes loading regimen (200mg weekly x4 then every other week) with 36-week dosing; topline data expected mid-2026.","Preliminary PK data shows steady state achieved earlier with loading regimen; signs of clinical activity observed among early patients.","Company plans to advance to pivotal trials pending Part B results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139939,"accession_number":"0000950170-25-103526","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.","Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.","SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.","Fast Track designation granted by FDA for bempikibart in alopecia areata.","Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157549,"accession_number":"0001193125-25-146179","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.","Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.","Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.","Topline results from Part B of SIGNAL-AA expected in first half of 2026.","Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157548,"accession_number":"0001193125-25-142039","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Q32 Bio stockholders approve officer exculpation charter amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment limiting officer liability (Delaware law) approved; effective June 16, 2025.","David Grayzel, Isaac Manke, and Diyong Xu elected Class I directors for three-year terms.","Ernst & Young ratified as independent auditor for FY 2025 with 99.9% votes for.","Say-on-pay advisory vote passed with 7.45M for; one-year frequency selected for future votes.","Adjournment proposal also approved (7.88M for) but not needed as Proposal 2 passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157547,"accession_number":"0001193125-25-125435","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.","Also failed market value ($35M) and net income ($0.5M) alternatives.","Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 days.","Bempikibart-related liability of $55M from Amgen re-acquisition contributes to deficit.","No immediate effect on listing; stock continues trading under QTTB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157546,"accession_number":"0000950170-25-066366","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q1 net loss $11.0M; cash $65.5M, runs into 2H'26; first patient dosed in Phase 2a Part B for AA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).","Cash and equivalents $65.5M as of March 31, 2025; expected to fund operations into 2H'26.","First patient dosed in SIGNAL-AA Phase 2a Part B; topline data expected 1H'26.","Fast Track designation granted to bempikibart for alopecia areata; durable responses seen in late-breaking AAD presentation.","First patient dosed in Part A open-label extension; median follow-up 41 weeks shows maintenance or further hair growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157545,"accession_number":"0001193125-25-096703","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Q32 Bio director Mark Iwicki to resign from board, effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Iwicki notified his resignation from the board on April 25, 2025, effective December 31, 2025.","He will remain Chair and Compensation Committee chair, and Audit Committee member until the effective date.","Resignation is to reduce board commitments; no disagreement with the company.","He will continue as CEO of Inhibikase Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175919,"accession_number":"0000950170-25-036819","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.","Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.","SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.","Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).","Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175918,"accession_number":"0001193125-25-050372","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.","Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.","Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.","OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.","All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175917,"accession_number":"0000950170-25-017075","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.","Expects $1.1M severance charges; cash runway extended to second half of 2026.","Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.","Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175916,"accession_number":"0001193125-25-004976","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Q32 Bio updates corporate presentation for investor meetings; no financial details given","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation updated as of January 13, 2025, available on company website.","Overview covers immune therapeutics pipeline but no new financial or strategic data disclosed.","No material changes to guidance, pipeline, or leadership reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192831,"accession_number":"0001193125-24-274856","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio reports mixed Phase 2a results: AA signal, AD miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.","SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).","Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.","Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.","Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192830,"accession_number":"0000950170-24-122770","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.","Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.","Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.","ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.","Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209248,"accession_number":"0000950170-24-093295","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.","Cash and investments $107.6M as of June 30; expected funding into mid-2026.","Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.","ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.","Bempikibart AA Phase 2 topline results also expected in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209247,"accession_number":"0000950170-24-082307","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.","Part B randomized 1:1 to bempikibart 200 mg Q2W SC or placebo for 12 weeks.","Primary endpoint: mean % change from baseline in EASI score at week 14.","SIGNAL-AA (alopecia areata) enrollment also completed; both topline data due Q4 2024.","CEO cites patient demand as driver of enrollment surpassing initial target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227190,"accession_number":"0000950170-24-056256","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.","Completed enrollment in bempikibart Phase 2 alopecia areata trial; topline results expected Q4 2024.","ADX-097 renal basket Phase 2 trial to start H1 2024; initial data expected by year-end 2024.","Reverse merger with Homology Medicines closed in March 2024; concurrent $42M private placement.","Net income of $1.0M due to $15.9M gain on convertible note conversion; R&D expense $9.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246075,"accession_number":"0001193125-24-077930","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","2.01","9.01","5.02","2.02","2.03","3.02","3.03","4.01","5.01","5.03","5.06","7.01"],"status":"ready","headline":"Q32 Bio completes reverse merger with Homology Medicines; raises $42M in pre-closing financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed March 25, 2024; former Homology renamed Q32 Bio Inc., trading as QTTB on Nasdaq.","Pre-closing financing of $42M (35M shares at ~$1.20/share) from accredited investors.","Homology stockholders receive one CVR per share for potential payments from legacy asset sales (HMI-103, etc.).","New board and officers installed; lock-up agreements for 180 days for certain stockholders and executives.","Post-merger shares outstanding ~11.93M; reverse stock split 1:18 effected March 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246069,"accession_number":"0001193125-24-074775","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K/A","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Homology Medicines: reverse stock split effective March 26; Nasdaq listing approved for combined company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.","Stockholders to receive cash for fractional shares based on March 25 closing price.","Nasdaq Staff approved initial listing application for continued listing of Homology common stock post-merger with Q32.","Reverse split is part of the merger with Q32 Bio Inc.; Q32 will survive as a wholly owned subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246074,"accession_number":"0001193125-24-072689","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Homology Medicines approves 1-for-18 reverse stock split effective March 25 in connection with Q32 merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reverse stock split at 1-for-18 ratio; every 18 shares combine into one.","Reverse split effective at market open on March 25, 2024; Certificate of Amendment filed March 22.","No fractional shares issued; stockholders receive cash in lieu based on March 22 closing price.","Reverse split is a condition to closing of the merger with Q32 Bio Inc.","Post-split common stock trades under new CUSIP 746964105."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246073,"accession_number":"0001193125-24-069285","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Homology stockholders approve all merger-related proposals with Q32 Bio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stock Issuance Proposal passed: 35M for, 4.2M against, 9.3M broker non-votes.","Authorized shares increased to 400M, and reverse stock split (1:10 to 1:30) approved.","2024 Stock Option Plan and ESPP approved; Merger compensation advisory also passed.","Adjournment proposal approved but not needed as all key proposals passed.","Special Meeting had 48.6M shares present (83.6% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246072,"accession_number":"0001193125-24-064315","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Homology discloses lawsuit and demand letters challenging Q32 merger; provides supplemental proxy disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Stockholder Kevin Welsh filed a putative class action on Feb 22, 2024 under Sections 14(a) and 20(a) alleging material omissions in the merger proxy statement.","Twelve other purported stockholders sent demand letters with similar allegations regarding the proxy statement.","Company denies all allegations and believes proxy complies with law, but voluntarily supplements disclosures to moot claims without admitting liability.","Supplemental disclosures include additional details on TD Cowen's DCF analysis: perpetuity growth rate of (33)%, probability of success 15%-30%, discount rates 14%-17%.","Separate 2022 securities class action (Pizzuto) remains pending; oral argument on motion to dismiss held March 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246071,"accession_number":"0001193125-24-016726","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Homology Medicines furnishes Q32 Bio investor presentation for proposed merger; cash runway into mid-2026","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Presentation highlights Q32's pipeline: bempikibart (phase 2 for alopecia areata/atopic dermatitis) and ADX-097 (phase 1/2 for complement-mediated diseases).","Combined company expects cash, cash equivalents and short-term investments to fund operations into mid-2026.","Merger expected to close in Q1 2024, subject to Homology stockholder approval and other customary conditions.","CVRs may provide contingent payments to Q32 stockholders based on future milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246070,"accession_number":"0001193125-24-001519","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Homology Medicines receives Nasdaq bid price deficiency notice; compliance deadline June 26, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Dec 29, 2023 for bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days, until June 26, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.","Plans to seek stockholder approval for reverse stock split in connection with proposed merger with Q32 Bio.","If not compliant by June 26, may qualify for second 180-day period by transferring to Nasdaq Capital Market.","Failure could lead to delisting, subject to appeal; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263534,"accession_number":"0001193125-23-278334","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","9.01"],"status":"ready","headline":"Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.","Q32 to raise $42M in concurrent financing from accredited investors immediately before close.","Combined board to have 9 members: 2 from Homology, 7 from Q32 (indicating Q32 control).","Q32 holders with 74.1% of Q32 capital stock and Homology holders with 18.2% of common stock support deal via support agreements.","CEO Albert Seymour and CFO W. Bradford Smith terminated; Paul Alloway named President/COO/PEO; Charles Michaud named VP/Controller/Treasurer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263533,"accession_number":"0001193125-23-278325","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Homology Medicines to merge with Q32 Bio; Q32 shareholders to own 75%, combined company targets autoimmune pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Homology issues stock to Q32 holders; pre-merger Homology shareholders own ~25%, Q32 ~75%; CVR issued for legacy asset proceeds.","Concurrent $42M private placement (OrbiMed, Atlas, Bristol Myers Squibb, etc.) to fund Phase 2 trials of bempikibart and ADX-097.","Combined company expects ~$115M cash at close, runway to mid-2026; Homology discontinues R&D, including PKU gene therapy HMI-103.","Q32 reacquired worldwide rights to bempikibart (anti-IL-7Rα) from Amgen; Phase 2 topline data for atopic dermatitis & alopecia areata in 2H 2024.","ADX-097 (tissue-targeted complement inhibitor) Phase 1 safety positive; Phase 2 basket trial start expected with proof-of-concept data by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263532,"accession_number":"0001193125-23-253563","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Homology Medicines posts corporate slides; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted a corporate slide presentation on its investor relations website on October 10, 2023.","Presentation attached as Exhibit 99.1; no specific financial or operational updates provided in the filing.","No earnings, guidance, or material events announced; presentation content not detailed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280749,"accession_number":"0001193125-23-196284","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Homology Medicines cuts ~80 employees, initiates strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force of ~80 employees, including CMO Julie Jordan; CCO Michael Blum retained as consultant.","Estimated restructuring charges of ~$6.8M (severance, benefits) expected in Q3 2023.","Board begins process to explore strategic options including acquisition, merger, or sale of assets.","Actions aimed at reducing operating expenses and maximizing shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299370,"accession_number":"0001193125-23-166857","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Homology Medicines shareholders elect two Class II directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Steven Gillis, Ph.D. elected with 32,246,621 votes for and 2,619,932 withheld; 10,698,943 broker non-votes.","Albert Seymour, Ph.D. elected with 34,681,867 votes for and 184,686 withheld; 10,698,943 broker non-votes.","Ratification of Deloitte & Touche LLP as independent auditor approved: 44,765,597 for, 108,239 against, 691,660 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319526,"accession_number":"0001193125-23-001587","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Homology Medicines posts corporate slide presentation on website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted a corporate slide presentation on its investor relations website on January 4, 2023.","Presentation attached as Exhibit 99.1 to Form 8-K; no specific financial or operational updates disclosed.","No new guidance, material events, or changes to business strategy described in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355099,"accession_number":"0001193125-22-240991","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.","Seymour received option for 23,000 shares at $2.18 and 14,000 RSUs, vesting over 48 months and 3 years.","Arthur Tzianabos resigned as CEO, appointed Chairman of Board; consulting agreement pays $26,571/month through March 31, 2023.","Kush Parmar resigned from Board and Chairman role; Jeffrey Poulton appointed Lead Director.","CFO W. Bradford Smith's severance amended: 12 months base salary continuation on qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373182,"accession_number":"0001193125-22-175494","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Homology Medicines stockholders elect Poulton and Reicin, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeffrey V. Poulton re-elected with 34,128,578 votes for, 4,032,293 withheld.","Alise S. Reicin, M.D. re-elected with 33,811,623 votes for, 4,349,248 withheld.","Ratification of Deloitte & Touche as auditor approved: 48,122,966 for, 421,138 against.","Approximately 84.85% of outstanding shares were represented at the June 15, 2022 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373181,"accession_number":"0001193125-22-172488","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA lifts clinical hold on Homology's pheNIX gene therapy trial for HMI-102 in PKU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold on pheNIX trial (HMI-102) for phenylketonuria; company resolved all issues from March 17, 2022 hold.","Clinical hold related to elevated liver function tests, all resolved without hospitalizations.","Protocol changes include steroid-sparing immunosuppression with tacrolimus and shorter steroid course.","Company plans to provide program update in fall 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373180,"accession_number":"0001193125-22-113203","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Homology appoints Albert Seymour President; Tzianabos remains CEO, Seymour gets new equity grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Albert Seymour promoted to President effective April 21, 2022, while remaining Chief Scientific Officer.","Arthur Tzianabos resigns as President but continues as Chief Executive Officer of Homology.","Seymour's base salary increased to $545,000; target annual bonus set at 50% of base salary.","Seymour receives option to purchase 60,000 shares at $1.78, vesting over 48 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391935,"accession_number":"0001193125-22-077227","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Homology closes $130M AAV manufacturing JV with Oxford; retains 20% stake plus put/call option","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Homology transferred AAV manufacturing assets to Newco for 175,000 units, then sold 130,000 units to OXB for $130M cash.","OXB contributed $50M for 50,000 units; post-closing OXB owns 80%, Homology owns 20% of Newco.","After three years, Homology can put (or OXB can call) Homology's Newco stake at 5.5x trailing revenue, subject to cap.","Pro forma shows estimated gain of $145M on derecognition of assets and equity method investment of $45M as of Sept 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391934,"accession_number":"0001193125-22-046610","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA places Homology's pheNIX gene therapy trial for PKU on clinical hold due to elevated liver tests","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Homology on Feb 16, 2022 that HMI-102 trial is on clinical hold to modify risk mitigation for elevated liver function tests.","Company expects official clinical hold letter within 30 days and will provide update after FDA interactions.","Clinical hold does not affect CMC/manufacturing or other programs (HMI-103 gene editing, HMI-203 for Hunter syndrome).","Homology expects program updates for HMI-103 and HMI-203 by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391933,"accession_number":"0001193125-22-025957","cik":1661998,"company_name":"Q32 Bio Inc.","ticker":"QTTB","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Homology forms AAV manufacturing JV with Oxford; receives $130M; owns 20% of Newco","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Homology receives $130M upfront from Oxford Biomedica; Oxford invests $50M additional into Newco.","Post-closing OXB owns 80% and Homology 20% of Oxford Biomedica Solutions LLC.","Tim Kelly, Homology's COO, becomes CEO and Chairman of Newco; Arthur Tzianabos on board.","Oxford Biomedica CEO John Dawson retires; Dr. Roch Doliveux named interim CEO.","Transaction expected to close Q1 2022, subject to HSR antitrust clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":181070760.13044357,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-03T23:59:59+00:00|391933"}